163 0 Kommentare Celsion Corporation Announces Formation of Vaccine Advisory Board - Seite 2

Dr. Yang has global experience leading cross-functional teams to develop products from scientific discovery to preclinical to clinical evidence development. He has advanced expertise in virology, vaccinology and immunology with extensive research and teaching experience in leading institutions in academia and in the pharmaceutical industry. He currently serves as a consultant for the Gerson Lehman Group. Previously, Dr. Yang joined Pfizer in 2014 and held positions of increasing responsibility, serving as Director, Viral Vaccines and Program Lead of The HCMV (human cytomegalovirus) Vaccine program. At Pfizer he served as a member of the Vaccine Technical Review Committee and as a member of Vaccine Clinical Review Committee. Previously he served on the faculty of the Chinese Academy of Preventive Medicine, where he led pioneering epidemiological studies on HIV/AIDS in China. Dr. Yang has published many peer-reviewed articles.

Dr. Yang earned an M.S. in epidemiology and holds the M.D. degree equivalent from Fudan University (formerly the Shanghai Medical University) and a Ph.D. in Molecular Virology from Baylor College of Medicine. He was a postdoctoral research fellow at Harvard Medical School, where he also was an Instructor of Pathology and Assistant Professor of Medicine and Virology.

About the PLACCINE platform

PLACCINE is Celsion’s proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines and was announced on January 28, 2021. An adaptation of the Company’s TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens along with a potent immune modifier. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:

Viral Mutations: PLACCINE may offer broad-spectrum and mutational resistance (variants) by targeting multiple antigens on a single plasmid vector.
Enhanced Efficacy: The potent immune modifier IL-12 may improve humoral and cellular responses to viral antigens and can be incorporated in the plasmid.
Durable Efficacy: PLACCINE delivers a DNA plasmid-based antigen that can result in durable antigen exposure and a robust vaccine response to viral antigens.
Storage & Distribution: PLACCINE allows for stability that is compatible with manageable vaccine storage and distribution.
Dosing & Administration: PLACCINE is a synthetic delivery system that should require a simple injection that does not require viruses or special equipment to deliver its payload.